Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Phase 2
Recruiting
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Drug: Bortezomib
First Posted Date
2018-07-18
Last Posted Date
2024-02-09
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
250
Registration Number
NCT03590171
Locations
🇩🇰

Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark

🇳🇴

Oslo University Hospital, Oslo, Norway

🇵🇱

Dpt. SCT and Hematology/Oncology University Wroclaw, Wroclaw, Poland

and more 12 locations

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

First Posted Date
2018-07-17
Last Posted Date
2021-02-04
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
62
Registration Number
NCT03589222
Locations
🇪🇸

Hospital Germans Trials i Pujol, Badalona, Spain

🇪🇸

Hospital Clinic de Barcelona, Barcelona, Spain

🇪🇸

Hospital ICO de Girona, Girona, Spain

and more 12 locations

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted Date
2018-06-01
Last Posted Date
2024-05-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
153
Registration Number
NCT03544281
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

First Posted Date
2018-05-03
Last Posted Date
2020-09-01
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
12
Registration Number
NCT03515200
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

First Posted Date
2018-03-29
Last Posted Date
2022-12-19
Lead Sponsor
Oncopeptides AB
Target Recruit Count
56
Registration Number
NCT03481556
Locations
🇨🇿

Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia

🇨🇿

Fakultní nemocnice Ostrava, Ostrava, Czechia

🇫🇷

Hôpital Morvan, Brest, France

and more 13 locations

Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

First Posted Date
2018-02-23
Last Posted Date
2018-02-23
Lead Sponsor
Shandong University
Target Recruit Count
200
Registration Number
NCT03443570
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

First Posted Date
2018-01-31
Last Posted Date
2022-09-27
Lead Sponsor
Takeda
Target Recruit Count
45
Registration Number
NCT03416374
Locations
🇯🇵

Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan

🇯🇵

Kyorin University Hospital, Mitaka, Tokyo, Japan

🇯🇵

Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

and more 20 locations

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

First Posted Date
2018-01-26
Last Posted Date
2024-05-24
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
265
Registration Number
NCT03412565
Locations
🇺🇸

Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States

and more 60 locations

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

First Posted Date
2018-01-17
Last Posted Date
2021-02-23
Lead Sponsor
Jian Li
Target Recruit Count
140
Registration Number
NCT03401372
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

First Posted Date
2018-01-04
Last Posted Date
2020-02-05
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
4000
Registration Number
NCT03390387
Locations
🇷🇺

Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation

🇦🇲

prof. R.O.Eolyan Hematology Center, Ereván, Armenia

🇷🇺

Transbaikal Regional Oncology Dispensary, Chita, Russian Federation

and more 45 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy